End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation.
Guo Y, Han J, Zhang Y, Jin C, Zhang Y, He J, Chen S, Guo Y, Lin Y, Li F, Yang F, Shen Z, Mao R, Zhu H, Zhang J.
Guo Y, et al. Among authors: zhang j, zhang y.
Front Cell Infect Microbiol. 2023 Feb 24;13:1120300. doi: 10.3389/fcimb.2023.1120300. eCollection 2023.
Front Cell Infect Microbiol. 2023.
PMID: 36909726
Free PMC article.